About Us

Dr. David Ren is the founder and Chief Science Officer of Reniguard Life Sciences Inc. Dr. Ren received his medical degree from Shanghai Medical University (now Medical College of Fudan University) and a PhD degree in Molecular Biology from the University of Oxford. His postdoctoral research at The Scripps Research Institute was on cell signaling by extracellular matrices and oncogenes. He then worked as an Assistant Professor at SUNY Stony Brook on wound healing biology and translational research. In 2008, Dr. Ren started DNA biomarker studies and founded Reniguard Life Sciences Inc.

Dr. Ren has strong passion in improving patient management via medical research. Dr. Ren developed ELISA kits for HCMV IgG and IgM antibodies in his early research career. He is a technical expert holding several patents and one of his inventions (Rho activity assay; developed at Scripps) is now being commercialized at Millipore. At Reniguard, a number of cutting edge PCR technologies have been developed and several molecular assays are being developed and evaluated. We value academic excellence and technical innovations at Reniguard.

We are very interested in strategic partnership with pharmaceutical companies and other biotech companies so that we could better serve the patients and improve their life quality.